Please assess the completion status of the following clinical trial:

Trial Title: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed amyloidosis~  * No secondary familial or localized amyloidosis~* Presence of monoclonal protein by immunoelectrophoresis or immunofixation of serum or urine~* No primary amyloidosis manifested only by carpal tunnel syndrome or purpura~* Amyloid deposits in a plasmacytoma or in bone marrow vessels in an asymptomatic individual not considered an amyloid syndrome~  * Amyloid syndromes include any of the following:~    * Hepatomegaly~   * Cardiomyopathy~   * Nephrotic range proteinuria~   * Peripheral or autonomic neuropathy~* No multiple myeloma defined by 1 of the following:~  * Presence of lytic bone disease~ * More than 30% bone marrow plasma cells~PATIENT CHARACTERISTICS:~Age~* 18 to 70~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Platelet count at least 100,000/mm\^3~Hepatic~* See Disease Characteristics~* Total or direct bilirubin no greater than 2.0 mg/dL~* Alkaline phosphatase no greater than 4 times upper limit of normal~Renal~* See Disease Characteristics~* Creatinine less than 3.0 mg/dL~Cardiovascular~* See Disease Characteristics~* Ejection fraction at least 45% by echocardiogram~* No New York Heart Association class III or IV heart disease~* Systolic blood pressure ≥ 90 mmHg~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection~* No other malignancy within the past 5 years except surgically treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or indolent prostate cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 4 weeks since prior interferon~Chemotherapy~* At least 4 weeks since prior melphalan~* Lifetime total melphalan dose less than 150 mg/m\^2 (based on ideal body weight)~Endocrine therapy~* At least 4 weeks since prior dexamethasone~Radiotherapy~* No prior radiotherapy for amyloidosis~Surgery~* Not specified~Other~* No antihypertensive medications for at least 24 hours prior to, during, and for 1 hour after amifostine administration~* No other prior treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Amifostine, Melphalan, and Stem Cell Reconstitution (Type: EXPERIMENTAL): Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).